Guest Editor:

Prof. Dr. Wen Wee Ma
Professor of Oncology, Division of Medical Oncology, Mayo Clinic,
200 First Street SW Rochester, MN 55905, USA
ma.wen@mayo.edu

Deadline for manuscript submissions: 
closed (30 November 2017)

Message from the Guest Editor

Dear Colleagues,

Advancement in pancreatic cancer management has been dishearteningly slow. In the age of molecularly-targeted drugs and immunotherapy, the best treatment option for advanced and metastatic patients, which is the majority, remain combinations of cytotoxic drugs. For those fortunate enough to undergo curative pancreatectomy, cancer recurrence continues to be a real and significant concern. This Special Issue will discuss recent development in our understanding of the biology and genomic characteristics, early detection research, innovations in the treatment of localized disease and therapeutics targeting novel targets in pancreatic cancer.

Prof. Dr. Wen Wee Ma
Guest Editor
Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

**CiteScore** (2018 Scopus data): **5.87**, which equals rank 26/321 (Q1) in 'Oncology' and rank 24/191 (Q1) in 'Cancer Research'.